ReviewMicrobial cell factories2025
Engineering Bacillus subtilis for high-value bioproduction: recent advances and applications.
Review in Microbial cell factories, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- From gene to enzyme: Microbial engineering of bovine chymosin for efficient cheese coagulation.World journal of microbiology & biotechnology · 2026Article
- Overcoming cellular secretion bottlenecks: advanced secretion engineering and molecular tailoring for next-generation microbial α-amylases with enhanced industrial performance.World journal of microbiology & biotechnology · 2026Review
- Construction and Evaluation of High-Efficiency Tannase-Producing Strains.Microorganisms · 2026Article
- Engineering Bacillus Subtilis for Efficient Biosynthesis of Riboflavin: Current Knowledge and Future Perspectives.Applied biochemistry and biotechnology · 2026Review
- Bacillus-derived antimicrobial peptides as alternatives to antibiotics in poultry: mechanisms, applications, and future prospects- a review.Archives of microbiology · 2026Review
- Engineered live bacteria for liver diseases and gut-liver axis disorders: from genetic modification to advanced delivery systems.Journal of nanobiotechnology · 2026Review
- Advances in metabolic engineering of Bacillus subtilis towards high-efficiency cytidine biosynthesis.World journal of microbiology & biotechnology · 2026Review
- Formulated Diet Instead of Chilled Fish Is Beneficial to Microbial and Water Quality in Mandarin Fish (Siniperca chuatsi) Ponds.Current microbiology · 2026Article
- Synthetic biology for heparin biomanufacturing.Bioresources and bioprocessing · 2026Review
- Advances in gene editing tools for four typical Gram-positive bacteria.Frontiers in microbiology · 2026Review
- Exploring black soil microbiota for industrial enzymes: cellulase and xylanase characterization from Bacillus subtilis SSMK413.Microbial cell factories · 2025Article
- Expanding the Terpene Universe: Synthetic Biology and Non-Natural Chemistry in Engineered Microorganisms.Molecules (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bacillus subtilis, a key model strain in microbial physiology and biochemistry research, is non-pathogenic, secretes proteins efficiently, and has a clear genetic background, making it an ideal host for producing heterologous proteins, such as small molecules, bulk chemicals, enzymes, and functional peptides. In recent years, the synthetic biotechnology and metabolic engineering methods for B. subtilis have advanced rapidly, providing excellent tools and theoretical references for producing target products using this chassis cell. This review systematically summarizes strain optimization strategies via screening and modification of wild-type B. subtilis strains as expression hosts, promoter engineering, fine-tuning gene expression based on proteases and molecular chaperones, plasmid-based expression systems regulation, as well as its applications. Detailed analysis was conducted from a novel perspective on the comparison between B. subtilis and E. coli as hosts for biological production. Furthermore, the review delves into important considerations and future research directions for optimizing B. subtilis expression systems in industrial production. With the development of gene editing and synthetic biology technologies, and the continuous optimization of strain improvement strategies, B. subtilis will demonstrate tremendous potentials as a major microbial cell factory for the industrial production of protein products.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.